Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Asenapine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 8/20 | 1.00 |
| ▸ | HTR2A known ✓ | P28223 | 7/20 | 1.00 |
| ▸ | HTR2C | P28335 | 7/20 | 1.00 |
| ▸ | DRD3 | P35462 | 5/20 | 1.00 |
| ▸ | HRH1 | P35367 | 5/20 | 1.00 |
| ▸ | DRD4 | P21917 | 5/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 4/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 4/20 | 1.00 |
| ▸ | DRD1 | P21728 | 4/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 2/20 | 1.00 |
| ▸ | HTR1A | P08908 | 2/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 2/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 2/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 2/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
| ▸ | HTR2B | P41595 | 2/20 | 1.00 |
| ▸ | HTR3A | P46098 | 2/20 | 1.00 |
| ▸ | HTR6 | P50406 | 2/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Asenapine SCHEMBL30544842 | 1.00 | DRD2 (1.00) | DRD2HTR2AHTR2CDRD3HRH1 | |
| Asenapine SCHEMBL30413463 | 1.00 | DRD2 (1.00) | DRD2HTR2AHTR2CDRD3HRH1 | |
| Asenapine SCHEMBL29608307 | 1.00 | DRD2 (1.00) | DRD2HTR2AHTR2CDRD3HRH1 | |
| Asenapine SCHEMBL2221502 | 1.00 | DRD2 (1.00) | DRD2HTR2AHTR2CDRD3HRH1 | |
| Asenapine SCHEMBL3805507 | 1.00 | DRD2 (1.00) | DRD2HTR2AHTR2CDRD3HRH1 | |
| Asenapine SCHEMBL4060905 | 1.00 | DRD2 (1.00) | DRD2HTR2AHTR2CDRD3HRH1 | |
| Asenapine SCHEMBL30876933 | 1.00 | DRD2 (1.00) | DRD2HTR2AHTR2CDRD3HRH1 | |
| Asenapine SCHEMBL11537117 | 1.00 | DRD2 (1.00) | DRD2HTR2AHTR2CDRD3HRH1 | |
| Asenapine SCHEMBL8008417 | 1.00 | DRD2 (1.00) | DRD2HTR2AHTR2CDRD3HRH1 | |
| Asenapine SCHEMBL29365680 | 1.00 | DRD2 (1.00) | DRD2HTR2AHTR2CDRD3HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 9167 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146048-A1 | NOVEL BISINDOLYLMALEIMIDE KINASE INHIBITORS | 4M THERAPEUTICS INC. (US) | 2026-05-28 | — | — | US | claimed |
| CN-122042866-A | Method for separating, detecting and identifying flavonoid component in cocoa | 中国热带农业科学院香料饮料研究所 | 2026-05-15 | — | — | CN | claimed |
| EP-4725483-A1 | COMBINATION COMPRISING AT LEAST ONE 5-HT2A RECEPTOR ANTAGONIST AND AT LEAST ONE 5-HT3 RECEPTOR ANTAGONIST AND ITS MEDICAL USE | Université de Bordeaux (FR) | 2026-04-15 | — | — | EP | claimed |
| US-20260083759-A1 | Combinations Comprising Psychedelics for the Treatment of Schizophrenia and Other Neuropsychiatric and Neurologic Disorders | HADASIT MED RES SERVICE (IL) | 2026-03-26 | — | — | US | claimed |
| US-20260048062-A1 | FUSED AMINO PYRIMIDINE COMPOUNDS FOR TREATMENT OF PSYCHOSIS AND PSYCHOTIC DISORDERS | OVID THERAPEUTICS INC (US) | 2026-02-19 | — | — | US | claimed |
| US-20260027337-A1 | TRANSDERMAL DRUG DELIVERY DEVICES AND METHODS | MORNINGSIDE VENTURE INVESTMENTS LTD (MC) | 2026-01-29 | — | — | US | claimed |
| EP-3507371-B1 | COMPOSITIONS FOR TREATING DISEASES AND DISORDERS OF THE NERVOUS SYSTEM | UNIV RUTGERS (US) | 2026-01-28 | — | — | EP | claimed |
| EP-4049681-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING AN ANTIPSYCHOTIC DRUG AND A VMAT2 INHIBITOR AND USES THEREOF | NEUROCRINE BIOSCIENCES INC (US) | 2026-01-07 | — | — | EP | claimed |
| EP-4674482-A2 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS ASSOCIATED WITH NEURODEGENERATIVE DISEASE OR IMPULSIVE SYMPTOMS ASSOCIATED WITH MENTAL DISEASE CONTAINING BREXPIPRAZOLE OR SALT THEREOF | Otsuka Pharmaceutical Co., Ltd. (JP) | 2026-01-07 | — | — | EP | claimed |
| US-12515030-B2 | Transdermal drug delivery devices and methods | MORNINGSIDE VENTURE INVESTMENTS LIMITED (MC) | 2026-01-06 | — | — | US | claimed |
| US-20050215571-A1 | Therapeutic combination for cognititon enhancement and psychotic disorders | PFIZER INC. | 2005-09-29 | — | — | US | claimed |
| US-20050209250-A1 | Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists | PFIZER INC | 2005-09-22 | — | — | US | claimed |
| WO-2005084654-A2 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING PSYCHIATRIC DISORDERS WITH COX-2 INHIBITORS ALONE AND IN COMBINATION WITH ANTIDEPRESSANT AGENTS | PHARMACIA CORPORATION (US) | 2005-09-15 | — | — | WO | claimed |
| WO-2005082370-A1 | COMBINATIONS OF AN ATYPICAL ANTIPSYCHOTIC AND AN AMINOMETHYLPYRIDYLOXYMETHYL/BENZISOXAZOLE AZABICYCLIC DERIVATIVES FOR TREATING CNS DISORDERS | PFIZER PRODUCTS INC. (US) | 2005-09-09 | — | — | WO | claimed |
| WO-2005079807-A1 | THERAPEUTIC COMBINATIONS OF ATYPICAL ANTIPSYCHOTICS WITH CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2005-09-01 | — | — | WO | claimed |
| US-20050171086-A1 | Compositions for treating CNS disorders | PFIZER INC | 2005-08-04 | — | — | US | claimed |
| WO-2005063296-A2 | THERAPEUTIC COMBINATION FOR COGNITION ENHANCEMENT AND PSYCHOTIC DISORDERS | PFIZER PRODUCTS INC. (US) | 2005-07-14 | — | — | WO | claimed |
| US-20050004106-A1 | Combinations of GABA modulators and anticonvulsants, and atypical antipsychotics | PFIZER INC | 2005-01-06 | — | — | US | claimed |
| WO-2004110437-A1 | ASENAPINE FOR THE TREATMENT OF SCHIZOPHRENIA IN A PATIENT WITH OVERWEIGHT OR PREDISPOSITION FOR OVERWEIGHT | ORGANON IRELAND LTD. (IE) | 2004-12-23 | — | — | WO | claimed |
| WO-2004100992-A2 | THERAPEUTIC COMBINATIONS OF ATYPICAL ANTIPSYCHOTICS WITH GABA MODULATORS, ANTICONVULSANTS OR BENZODIAZAPINES | PFIZER PRODUCTS INC. (US) | 2004-11-25 | — | — | WO | claimed |